Fosmidomycin, a novel chemotherapeutic agent for malaria.
about
Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malariaGenetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersFosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malariaThe MB2 gene family of Plasmodium species has a unique combination of S1 and GTP-binding domainsGenomics research and malaria control: great expectationsGenomics-enabled discovery of phosphonate natural products and their biosynthetic pathwaysStructures of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate reductoisomerase provide new insights into catalysisStructure of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in a quaternary complex with a magnesium ion, NADPH and the antimalarial drug fosmidomycinStructural studies on Mycobacterium tuberculosis DXR in complex with the antibiotic FR-900098Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparumAlternatives to currently used antimalarial drugs: in search of a magic bulletNew Insight into Isoprenoids Biosynthesis Process and Future Prospects for Drug Designing in PlasmodiumAn update on the rapid advances in malaria parasite cell biology.Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria.Antimalarial compounds in Phase II clinical development.Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii.Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparumComparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosis and Corynebacterium diphtheriae.Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malariaPharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malariaInadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria.Parasite plastids: approaching the endgame.The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs.A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents.A closer look at the spectroscopic properties of possible reaction intermediates in wild-type and mutant (E)-4-hydroxy-3-methylbut-2-enyl diphosphate reductase.The global pipeline of new medicines for the control and elimination of malariaProspects for the treatment of drug-resistant malaria parasites.Assessment of safety of the major antimalarial drugs.Prodrugs for the treatment of neglected diseases.FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicityBiochemistry of the non-mevalonate isoprenoid pathway.Emerging drugs for malaria.Targeting apicoplasts in malaria parasites.Viable screening targets related to the bacterial cell wall.From crystal to compound: structure-based antimalarial drug discovery.Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials.MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis.QSAR based predictive modeling for anti-malarial molecules.Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin.Treating malaria in pregnancy in developing countries: priorities in clinical research and drug development.
P2860
Q21034149-3E8D2156-2DFF-41C4-AC61-5E5EA1C186B7Q22330767-AF7031D9-2DAD-4E15-9ABC-708D58485D75Q24680404-F65C803B-E7D2-47AB-9D22-61163DABAF42Q24794216-4B78B570-8DD2-4734-8EE8-E2A6873FDCE3Q24806742-A8118793-2655-4AED-93AB-897BDE1F6ABAQ26864667-0AF4FB3D-5172-4889-86F7-2093607FF282Q27644732-02BC17FC-1A40-4226-90B7-1F25177A4979Q27645328-3F0B377A-ACE2-4186-8E65-57BAE24FA2BCQ27676911-17369E0C-5411-4A2A-BDA1-2343563587D5Q27677409-3A483905-BEB3-4C2D-AB0B-83B9C48F9EF8Q28070398-225D792C-1915-4EBA-82F5-EC1CACE7B6D8Q28078674-EB8B1339-4A28-4382-925B-B48EE5A7AD97Q33905946-85988B80-7E78-4A63-ADC5-CD1D7EDB51D3Q33935493-5681C64D-1BB8-4334-925B-5BE8F60CA089Q34456807-7DF6CCF5-4A66-4502-87A5-13F60673FDFBQ35102319-1E6CDF5B-92A7-4090-9BCD-D2A4D7D55623Q35635628-A1B8B215-823D-46CD-8D19-F1192554E6A4Q35756648-56916171-F57E-4DE2-A813-7BB3E7C6A602Q35759028-82E1E168-909D-4AD7-B9CC-A8C1043C1B72Q35850868-DDD9A84B-13C2-4BA5-A838-A20DD917F152Q36018812-246E2BA2-DBDC-4601-938B-7286E4F907C3Q36052586-03C70006-8C6F-46A1-BC5A-550AAEA8318EQ36066272-DE2084B8-88EB-4D98-A259-FC92AC75661DQ36172371-F99794FA-E1DF-4DC1-828C-0D8729F288A4Q36185966-928EABCE-2E80-4E3D-A98A-D996FB134A9EQ36320249-62CFD95B-6539-418E-84CA-7035ED85D0F7Q36895758-7FE9BB36-797A-401F-ADA1-1F77075E8114Q36945007-FE380717-4E13-4885-935D-7F2928F3DEF2Q37157236-CB907257-84A9-4A33-8323-C0F94080CC1CQ37189932-C375B6F7-815E-4394-8150-C901E62FBEC2Q37899789-019082BC-BB6F-4F50-96B6-CA581F90321BQ38027179-2708B738-0BD1-4138-AC78-8BD75800DCACQ38066563-1EE8B428-53E9-4328-91C8-7469384F2580Q38070780-B839FC74-9914-412A-8DF4-E9B47A0CFE9FQ38227796-8B1F0A8E-FC7B-4863-A63F-B5BA506A2029Q38558100-6B8A5504-8AAC-4FEB-A4AA-F0FDCBF7C79DQ38615212-6770EA1F-AB3D-42CF-B5CC-EEE98AE247ECQ38687538-56BF190A-266F-485B-9DE0-D716B94FFFF3Q38839163-6E9D3E91-0360-4412-9ACB-64384E727EA0Q39546704-3EB8C5FF-1316-4ACF-A184-185796171C6D
P2860
Fosmidomycin, a novel chemotherapeutic agent for malaria.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@ast
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@en
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@nl
type
label
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@ast
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@en
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@nl
prefLabel
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@ast
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@en
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@nl
P2093
P2860
P921
P1476
Fosmidomycin, a novel chemotherapeutic agent for malaria.
@en
P2093
Andreas Schindler
David Hutchinson
Hassan Jomaa
Jochen Wiesner
Martin Hintz
Michel Anoumou Missinou
Ronnatrai Ruangweerayut
Thomas Baranek
P2860
P304
P356
10.1128/AAC.47.2.735-738.2003
P407
P577
2003-02-01T00:00:00Z